COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.

Compass Pathways appoints Teri Loxam as Chief Financial Officer

Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

Acadia Healthcare

Teladoc

Mental health stocks are democratizing access to mental health services for millions across the globe. The lack of access to qualified counselors is a significant hurdle for people to get the help they need (primarily due to financial commitments).

Investing in Mental Health: 3 Stocks in the Wellness Space

LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference at 10:25 am ET on November 30, 2023.

Compass Pathways to participate in upcoming Evercore investor conference

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the initiation of the UK component of its phase 3 program of investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The research will take place in multiple sites in the UK, including at the Centre for Mental Health Research and Innovation (“the Centre”) in London, which officially opened today.

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Mary-Rose Hughes - Interim CFO Dr. Guy Goodwin - Chief Medical Officer Conference Call Participants Ritu Baral - TD Cohen Charles Duncan - Cantor François Brisebois - Oppenheimer Patrick Trucchio - H.C. Wainright Michael Okunewitch - Maxim Group Sumant Kulkarni - Canaccord Genuity Gavin Clark-Gartner - Evercore ISI Thomas Shrader - BTIG Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Third Quarter 2023 Conference Call.

COMPASS Pathways plc (CMPS) Q3 2023 Earnings Call Transcript

LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2023 and provided an update on recent progress across its business.

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Mike Falvey, Chief Financial Officer, will depart the company on November 3, 2023, to pursue other opportunities. Mary-Rose Hughes, current Vice President of Finance at COMPASS, will assume the role of interim CFO effective today. COMPASS has begun a search to select a permanent Chief Financial Officer.

COMPASS Pathways announces CFO transition

LONDON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2, 2023.

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

Psychedelic stocks are on the rise. Despite the stigma surrounding psychedelics for personal use, controlled medical experiments indicate their usefulness for treating a variety of conditions.

Don't Miss the Boom: 3 Psychedelic Stocks Set to Explode Higher

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

COMPASS Pathways PLC Sponsored ADR (CMPS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CMPS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy?

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a new paper in Pyschopharmacology, which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The paper was published on August 22, 2023.

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences:

COMPASS Pathways to participate in upcoming September investor conferences

Beam Therapeutics

908 Devices

Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.

3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has entered into a securities purchase agreement with a select group of healthcare specialist investors for the private placement of (i) 16,076,750 American Depositary Shares (“ADSs”) representing 16,076,750 ordinary shares, and (ii) warrants to purchase up to 16,076,750 ADSs (representing 16,076,750 ordinary shares) (the “Warrants”) at a purchase price of approximately $7.78 per ADS and accompanying Warrant to purchase one ADS. Each Warrant will have an exercise price of $9.93 per ADS, representing a 30% premium to the last sale price. The financing is expected to close on August 18, 2023, subject to customary closing conditions.

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

COMPASS Pathways plc (NASDAQ:CMPS ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Officer Mike Falvey - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen and Company, LLC Charles Duncan - Cantor Fitzgerald Patrick Trucchio - H.C. Wainwright & Co, LLC Francois Brisebois - Oppenheimer & Co. Elemer Piros - EF Hutton Thomas Shrader - BTIG Kyle Qian - Canaccord Genuity Michael Okunewitch - Maxim Group LLC Operator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Second Quarter 2023 Conference Call.

COMPASS Pathways plc (CMPS) Q2 2023 Earnings Call Transcript

LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the second quarter 2023 and gave an update on recent progress across its business.

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2023, and provide an update on recent business developments on August 3, 2023.

COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023

COMP360 appears to be compatible with certain antidepressant medications. That's contrary to some prior assumptions, so it's a pleasant surprise.

This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock

COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa COMP360 psilocybin treatment shows potential in exploratory open-label investigator-initiated study in anorexia nervosa

First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine

LONDON, July 17, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that positive data from an open-label phase 2 clinical trial of investigational COMP360 psilocybin in addition to daily selective serotonin reuptake inhibitors (SSRIs) in treatment-resistant depression has been published online in the peer reviewed Nature journal, Neuropsychopharmacology .

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

Atai Life Sciences BV

Cybin

Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock.

Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.

A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway. COMPASS Pathways is short on cash but has major investment house backing.

News for COMPASS Pathways Stock (CMPS)